Linked Data API

Show Search Form

Search Results

1142432
star this property registered interest false more like this
star this property date less than 2019-07-25more like thismore than 2019-07-25
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Pensions more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have, if any, to compensate senior NHS staff who have inadvertently exceeded the tapered annual pensions allowance. more like this
star this property tabling member printed
Baroness Altmann more like this
unstar this property uin HL17506 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>For the majority of people, their pension contributions are tax-free. This makes pensions tax relief one of the most expensive reliefs in the personal tax system. The reforms to the lifetime and annual allowance made in the previous two parliaments are expected to save over £6 billion per year and are necessary to deliver a fair system and protect public finances. Less than 1% of pension savers will have to reduce their saving or face an annual allowance charge as a result of the tapered annual allowance.</p><p>While there are no plans to compensate senior National Health Service staff who exceed their tax-free pension savings allowances, the Scheme Pays facility is there to assist NHS Pension Scheme members who breach the annual allowance, and allows them to settle their lifetime and annual allowance charges without making an upfront payment. The Scheme Pays facility was recently extended to cover tax charges of any amount and those arising from the tapered annual allowance.</p><p>The Government has launched a full public consultation setting out proposals to make the NHS Pension Scheme more flexible for clinicians, to give them more control over their pension growth and tax liabilities.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
remove maximum value filtermore like thismore than 2019-08-06T15:06:30.857Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4533
star this property label Biography information for Baroness Altmann more like this
1141940
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Gambling: Rehabilitation more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 17 July (HL16963 and HL16964), what was the budget of Leeds and York Partnership NHS Trust for funding the NHS Northern Gambling Clinic; and what is the projected cost of that clinic in (1) 2020, (2) 2021, and (3) 2022. more like this
star this property tabling member printed
The Lord Bishop of St Albans more like this
unstar this property uin HL17484 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>NHS England and NHS Improvement have allocated £600,000 to Central and North West London NHS Foundation Trust and £370,000 to Leeds and York Partnership NHS Foundation Trust for gambling harm services provision in 2019/20, which includes funding for these clinics.</p><p> </p><p>GambleAware, an independent charity, is providing additional funding for these clinics. Information on this funding is not held centrally.</p><p> </p><p>Future years’ funding is not yet available.</p><p> </p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17485 more like this
star this property question first answered
less than 2019-08-06T14:58:10.86Zmore like thismore than 2019-08-06T14:58:10.86Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4308
star this property label Biography information for The Lord Bishop of St Albans more like this
1141941
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading National Problem Gambling Clinic more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 17 July (HL16963 and HL16964), what was the budget of the Central and North West London NHS Foundation Trust for funding the National Problem Gambling Clinic; and what is the projected cost of that clinic in (1) 2020, (2) 2021, and (3) 2022. more like this
star this property tabling member printed
The Lord Bishop of St Albans more like this
unstar this property uin HL17485 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>NHS England and NHS Improvement have allocated £600,000 to Central and North West London NHS Foundation Trust and £370,000 to Leeds and York Partnership NHS Foundation Trust for gambling harm services provision in 2019/20, which includes funding for these clinics.</p><p> </p><p>GambleAware, an independent charity, is providing additional funding for these clinics. Information on this funding is not held centrally.</p><p> </p><p>Future years’ funding is not yet available.</p><p> </p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17484 more like this
star this property question first answered
less than 2019-08-06T14:58:10.893Zmore like thismore than 2019-08-06T14:58:10.893Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4308
star this property label Biography information for The Lord Bishop of St Albans more like this
1141957
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Breast Cancer: Drugs more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
unstar this property uin HL17501 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17502 more like this
star this property question first answered
less than 2019-07-25T16:45:03.16Zmore like thismore than 2019-07-25T16:45:03.16Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1141958
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Pertuzumab more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
unstar this property uin HL17502 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17501 more like this
star this property question first answered
less than 2019-07-25T16:45:03.207Zmore like thismore than 2019-07-25T16:45:03.207Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1141380
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading MMR Vaccine: Safety more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine. more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
unstar this property uin 280998 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> more like this
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:35:38.84Zmore like thismore than 2019-07-25T16:35:38.84Z
unstar this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1522
star this property label Biography information for Adam Holloway more like this
1141255
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Non-surgical Cosmetic Procedures: Children more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners. more like this
star this property tabling member constituency North Durham more like this
star this property tabling member printed
Mr Kevan Jones more like this
unstar this property uin 280927 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:32:36.833Zmore like thismore than 2019-07-25T16:32:36.833Z
unstar this property answering member
4065
star this property label Biography information for Jackie Doyle-Price more like this
star this property tabling member
1438
star this property label Biography information for Mr Kevan Jones more like this
1141356
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Sapropterin more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of whether Kuvan should be assessed through NICE's highly-specialised technology appraisal. more like this
star this property tabling member constituency North Durham more like this
star this property tabling member printed
Mr Kevan Jones more like this
unstar this property uin 280943 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>Decisions on whether individual medicines are suitable for assessment by the National Institute for Health and Care Excellence (NICE), and whether they meet the criteria for the highly specialised technologies programme, are taken through an established topic selection process.</p><p>The process is overseen by NICE and includes consideration against published criteria by a topic selection panel and engagement with stakeholders. Although NHS England, NHS Improvement and the Department provide input and are part of this panel, the decision-making process is led by NICE. Kuvan for the treatment of phenylketonuria was last considered by the topic selection panel on 15 February 2019.</p><p>In the absence of guidance from NICE, it is for National Health Service organisations and healthcare professionals to make decisions on whether to fund Kuvan on the basis of an assessment of the available evidence. Treatment for patients with phenylketonuria who are not receiving Kuvan or for who Kuvan is not effective includes dietary protein restriction combined with dietary supplements.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency Bury St Edmunds more like this
star this property answering member printed Jo Churchill more like this
star this property question first answered
less than 2019-08-06T14:36:02.507Zmore like thismore than 2019-08-06T14:36:02.507Z
unstar this property answering member
4380
star this property label Biography information for Jo Churchill more like this
star this property tabling member
1438
star this property label Biography information for Mr Kevan Jones more like this
1141460
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Health: Children more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to encourage health and wellbeing boards to measure and monitor children's subjective well-being as a key outcome in their local area. more like this
star this property tabling member constituency Vale of Clwyd more like this
star this property tabling member printed
Chris Ruane more like this
unstar this property uin 280948 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-29more like thismore than 2019-07-29
star this property answer text <p>Health and Wellbeing Boards in England bring into one forum representatives from health, social services and the local community to decide what the main public health needs of the local population are, and to determine how best to meet them in an integrated and holistic manner. Health and Wellbeing Boards are required to produce Joint Strategic Needs Assessment (JSNA) for their area. Based on the needs identified the Board produces a Joint Health and Wellbeing Strategy (JHWS). Both the JSNA and JHWS must be taken into account by local authorities, clinical commissioning groups and NHS England when preparing or revising commissioning.</p><p>We believe that local leaders are best placed to make decisions as to the need of the population they serve, including for children and young people’s wellbeing. Places such as Greater Manchester Combined Authority have produced a dedicated Children and Young People Health and Wellbeing Framework for 2018-2022.</p><p>As health is a devolved matter in Wales, it would therefore be the responsibility of the Welsh Government to decide how to monitor children’s wellbeing.</p><p> </p><p> </p><p> </p><p> </p>
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-07-29T09:42:45.747Zmore like thismore than 2019-07-29T09:42:45.747Z
unstar this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
534
star this property label Biography information for Chris Ruane more like this
1141282
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Electronic Cigarettes: Health Hazards more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the increased numbers of people vaping on (a) nicotine addiction, (b) incidences of increased blood pressure and (c) heart attack rates. more like this
star this property tabling member constituency North East Hampshire more like this
star this property tabling member printed
Mr Ranil Jayawardena more like this
unstar this property uin 281030 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-08-05more like thismore than 2019-08-05
star this property answer text <p>Public Health England (PHE) has published a series of reports on electronic cigarettes including the effects of vaping on health. The reports are available to view at the following link:</p><p><a href="https://www.gov.uk/government/collections/e-cigarettes-and-vaping-policy-regulation-and-guidance" target="_blank">https://www.gov.uk/government/collections/e-cigarettes-and-vaping-policy-regulation-and-guidance</a></p><p>While nicotine can contribute to raised blood pressure and cardiovascular risk, it is tar and carbon monoxide, which are the major sources of cardiovascular risk in cigarette smoke, producing nicotine vapour from a solution rather than by burning tobacco means that electronic cigarette vapour is free from almost all the toxic chemicals that accompany nicotine in cigarette smoke.</p><p>The Office for National Statistics has recorded the numbers of people using e-cigarettes since 2014 and the combined number of people using e-cigarettes and smoking has not increased since then. The proportion of people who smoke has decreased substantially in the same period.</p><p>PHE encourages people who both vape and smoke to stop smoking completely, because this greatly reduces health risks.</p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency Bury St Edmunds more like this
star this property answering member printed Jo Churchill more like this
star this property question first answered
less than 2019-08-05T11:25:52.907Zmore like thismore than 2019-08-05T11:25:52.907Z
unstar this property answering member
4380
star this property label Biography information for Jo Churchill more like this
star this property tabling member
4498
star this property label Biography information for Mr Ranil Jayawardena more like this